Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–135 of 135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Thrush Clear all

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: L-743,872; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rahway, New Jersey

Conditions: Candidiasis
Interventions: Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Invasive Candidiasis
Interventions: Micafungin; Drug
Lead sponsor: Kevin Watt; Other
Eligibility: Up to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Terbinafine hydrochloride; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Clotrimazole, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Los Angeles, California • Oakland, California • San Francisco, California + 12 more

Conditions: Candida Vulvovaginitis
Interventions: Fluconazole, SCY-078; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more

Conditions: Candidiasis, Candidemia
Interventions: voriconazole (Vfend); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more

Conditions: Candidiasis, HIV Infections
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Vulvovaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions: CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Davis, California • Miami, Florida + 12 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Posaconazole, Fluconazole; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 17
States / cities: Berkeley, California • San Francisco, California • Denver, Colorado + 13 more

Conditions: Candidemia
Interventions: Antifungal treatment; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions: Vaginal Swab Collection; Diagnostic Test
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 3,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Fullerton, California • Los Angeles, California • Pasadena, California + 16 more

Conditions: Aspergillosis, Candidemia, C. Difficile
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

Vaginal Ecosystem and Network in the United States Study

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients